Plus   Neg

Delta Air Lines Guides FY20 EPS In Line - Quick Facts

Delta Air Lines (DAL) on Thursday provided an update on the company's business strategy and 2020 financial targets ahead of its annual event for the investment community later in the day. The company initiated earnings and revenue growth guidance for the full-year 2020.

For fiscal 2020, the company now projects earnings in a range of $6.75 to $7.75 per share on revenue growth of 4 to 6 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $7.06 per share on revenue growth of 3.7 percent to $48.62 billion for the year. Analysts' estimates typically exclude special items.

"In 2020, we expect to maintain our margins while delivering another year of $4 billion in free cash flow. We will continue to deploy capital to reinvest in the business and remain committed to returning 70 percent of free cash flow to our owners," said Paul Jacobson, Chief Financial Officer.

As a part of its ongoing commitment to sustainability, Delta is making all travel related to the 2019 Investor Day carbon neutral through verified carbon offset credits with The Guatemalan Conservation Coast Project.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT